SEAL BEACH, Calif.--(BUSINESS WIRE)--Dendreon today announced new findings from a study evaluating PROVENGE ® (sipuleucel-T) as the first immunotherapy to generate a durable killer T-cell response ...
May 3, 2010 — Clinicians are likely to be hearing from patients about sipuleucel-T (Provenge, Dendreon), the immunotherapy that has just been approved by the US Food and Drug Administration (FDA) for ...
SEAL BEACH, Calif.--(BUSINESS WIRE)--Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, today announced publication of results from ...
SEATTLE, May 18, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced three abstracts accepted for poster presentation detailing clinical trial plans for PROVENGE® (sipuleucel-T) ...
SEATTLE and WASHINGTON, Oct. 1 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following PROVENGE® (sipuleucel-T) data presentations taking place at the 25th International ...
SEATTLE, May 18, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced three abstracts accepted for poster presentation detailing clinical trial plans for PROVENGE® (sipuleucel-T) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results